Published in J Clin Psychopharmacol on June 01, 2005
Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One (2014) 1.02
The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Br J Clin Pharmacol (2011) 0.81
Mediators of effects of a selective family-focused violence prevention approach for middle school students. Prev Sci (2012) 0.78
Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid. J Clin Psychopharmacol (2012) 0.78
Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics. Int J Neuropsychopharmacol (2014) 0.75
Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry (2009) 4.44
The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf (2012) 2.70
The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol (2006) 2.40
Prescribing trends in veterans with posttraumatic stress disorder. J Clin Psychiatry (2012) 1.73
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol (2014) 1.58
Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. Clin J Sport Med (2005) 1.49
Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord (2013) 1.46
Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother (2010) 1.46
Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit (2006) 1.45
Quetiapine for acute mania in bipolar disorder. Am J Health Syst Pharm (2007) 1.41
Antipsychotic-induced hyperprolactinemia. Pharmacotherapy (2009) 1.40
Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry (2004) 1.30
Anabolic steroids: a review for the clinician. Sports Med (2002) 1.22
Evaluation of the Iowa Medicaid pharmaceutical case management program. J Am Pharm Assoc (2003) (2004) 1.22
Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry (2002) 1.14
Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother (2008) 1.12
Challenges in estimating mortality risk from antipsychotics in people with Alzheimer's disease. Am J Psychiatry (2014) 1.09
Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev (2012) 1.08
The association of alcohol-induced blackouts and grayouts to blood alcohol concentrations. J Forensic Sci (2006) 1.08
The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum Psychopharmacol (2009) 1.08
The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc (2004) 1.07
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol (2008) 1.03
Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens (Greenwich) (2010) 1.03
Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res (2005) 1.03
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics (2009) 1.02
Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology (2006) 1.00
A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data. Pharmacoepidemiol Drug Saf (2012) 1.00
Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet (2005) 0.97
DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences. Epigenomics (2012) 0.94
Association of health literacy with medication knowledge, adherence, and adverse drug events among elderly veterans. J Health Commun (2012) 0.93
Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet (2005) 0.92
Clozapine-induced leukopenia successfully treated with lithium. Am J Health Syst Pharm (2007) 0.92
Geriatric conditions, medication use, and risk of adverse drug events in a predominantly male, older veteran population. J Am Geriatr Soc (2011) 0.92
The impact of posttraumatic stress disorder on blood pressure and heart rate in a veteran population. J Trauma Stress (2013) 0.91
The relationship of an anticholinergic rating scale with serum anticholinergic activity in elderly nursing home residents. Psychopharmacol Bull (2002) 0.90
Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. J Forensic Sci (2003) 0.90
Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy (2009) 0.90
CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit (2004) 0.88
Phobic anxiety in late-life in relationship to cognition and 5HTTLPR polymorphism. Psychiatr Genet (2005) 0.88
Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate? Mol Diagn Ther (2013) 0.88
The extent of potential antihypertensive drug interactions in a Medicaid population. Am J Hypertens (2002) 0.88
Factors associated with recovery from anorexia nervosa. J Psychiatr Res (2013) 0.88
LA allelic heterozygosity of the 5HTTLPR polymorphism is associated with higher cognitive function and lower interpersonal sensitivity. Psychiatr Genet (2007) 0.86
Fats and factors: lipid profiles associate with personality factors and suicidal history in bipolar subjects. PLoS One (2012) 0.86
Testosterone therapy in late-life major depression in males. J Clin Psychiatry (2002) 0.85
Genetic variations in TGFβ1, tPA, and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancer. J Thorac Oncol (2013) 0.85
Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia. Hum Psychopharmacol (2011) 0.85
Attention-deficit hyperactivity symptoms and disorder in eating disorder inpatients. Int J Eat Disord (2009) 0.84
The influence of cognitive impairment and behavioral dysregulation on daily functioning in the nursing home setting. Am J Psychiatry (2003) 0.84
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. Pharmacotherapy (2011) 0.84
Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry (2011) 0.83
C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit (2002) 0.83
Demographic differences in incidence for pituitary adenoma. Pituitary (2011) 0.82
Association of plasma ω-3 and ω-6 lipids with burden of disease measures in bipolar subjects. J Psychiatr Res (2012) 0.82
Prevalence and determinants of anticholinergic medication use in elderly dementia patients. Drugs Aging (2013) 0.82
A longitudinal analysis of antihypertensive drug interactions in a Medicaid population. Am J Hypertens (2004) 0.82
The influence of cognitive impairment and psychiatric symptoms on daily functioning in nursing facilities: a longitudinal study. Ann Clin Psychiatry (2002) 0.82
Increased polysedative use in veterans with posttraumatic stress disorder. Pain Med (2013) 0.82
Gender differences in prescribing among veterans diagnosed with posttraumatic stress disorder. J Gen Intern Med (2013) 0.82
Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet (2009) 0.82
Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet (2007) 0.82
Aligning clinical practice to PTSD treatment guidelines: medication prescribing by provider type. Psychiatr Serv (2013) 0.81
Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol (2009) 0.81
Risks and benefits of bladder antimuscarinics among elderly residents of Veterans Affairs Community Living Centers. J Am Med Dir Assoc (2013) 0.81
Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Res (2012) 0.80
Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit (2003) 0.80
Rivastigmine-induced dystonia. Am J Health Syst Pharm (2007) 0.80
Chryptochrome 2 variants, chronicity, and seasonality of mood disorders. Psychiatr Genet (2012) 0.80
Consistency of antidepressant and chronic nonpsychiatric medication use in a high-risk clinical population. Res Social Adm Pharm (2008) 0.80
Acamprosate. Expert Opin Drug Metab Toxicol (2010) 0.80
P-glycoprotein (PGP) polymorphisms and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects. J Sex Marital Ther (2013) 0.80
Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther (2008) 0.79
ω-3 fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA. Neurology (2013) 0.79
A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharmacol Bull (2002) 0.79
Osteoporosis screening and treatment in women with schizophrenia: a controlled study. Pharmacotherapy (2004) 0.79
The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit (2006) 0.78
Executive function in eating disorders: the role of state anxiety. Int J Eat Disord (2013) 0.78
Early discontinuation and suboptimal dosing of prazosin: a potential missed opportunity for veterans with posttraumatic stress disorder. J Clin Psychiatry (2015) 0.78
Diabetes prevalence estimates in schizophrenia and risk factor assessment. Ann Clin Psychiatry (2011) 0.78
5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol (2002) 0.78
5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacol Bull (2003) 0.78
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res (2010) 0.78
Rural access to clinical pharmacy services. J Am Pharm Assoc (2003) (2014) 0.78
Potentially inappropriate anticholinergic medication use in older adults with dementia. J Am Pharm Assoc (2003) (2015) 0.78
A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach. Psychopharmacol Bull (2010) 0.77
A pilot study investigating tumor necrosis factor-α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder. Ther Drug Monit (2013) 0.77